|Dr. James Garner M.A., MBA, MBBS, B.Sc (Hons), SAFin.||CEO, MD & Exec. Director||565.21k||N/A||44|
|Ms. Gabrielle Heaton BBUS (ACC), CPA||Director of Fin. & Admin.||61.3k||N/A||N/A|
|Dr. Peng Leong MBA, Ph.D.||Chief Bus. Officer||438.53k||N/A||N/A|
|Dr. Gordon Hirsch MBA, MBBCh, FCP(SA), BSc Hons||Chief Medical Officer||258.24k||N/A||N/A|
|Ms. Catherine Hill ACA, GAICD, BSc (Hons)||Company Sec.||113.2k||N/A||N/A|
Novogen Limited, a biotechnology company, develops anti-cancer drugs. The company has three technologies, which include phosphoinositide 3-kinase inhibitors, superbenzopyran, and anti-tropomyosin. It is developing GDC-0084, a novel targeted therapy that has completed Phase I clinical trial for the treatment of glioblastoma; Cantrixil, which is in Phase I clinical trials to treat ovarian cancer; and Trilexium, a novel therapy that is in early stage pre-clinical development for the treatment of various cancer types. The company has collaboration agreement with The University of York, The Childrens Cancer Institute Australia, The Mater Institute in Queensland, and the University of Boston. Novogen Limited was founded in 1994 and is headquartered in Hornsby, Australia.
Kazia Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.